James Always appreciate your posts Being cognitively impaired as I am after almost 30yrs of Statin use :) I'll just observe the following
Th P value for the LDL number of 130 you are using for both groups is .822 ....it needs to be under .05 to rule out chance . Now its very likely that the LDL was reduced to 130 from 170 ...low and medium dose simavastain will lower LDL by at least 26% ( from 178 LDL to start with -26% on simavastatin can get you there ) ...but you are still probably 30% higher LDL levels then in the average Reduce It group .
Remember that the target for almost everyone in RI is LDL of less then 70 ...we don't know the mean but assume its an LDL of 90 ( you have to be under 100 to even be in the trial .... at 90 thats 30% less then the Jelis SIG group.
Going from memory ..about 22% of the Jelis SIG group were smokers I expect that to be a lot less in RI ...anyone that meets the requirements to be in RI ...at least the few that I have meet that qualified for the trial ...after their MI or stents or cardiac caths ...seem to have got religion about the risk of smoking.
I agree that Vascepa will show benefit . I'm just not convinced yet that the benefit will be great enough to stop the trial before Amarin runs out of cash .
I still maintain a long position so I'll be quite happy to be proven wrong Kiwi PS thanks for the link
News 
Market Data 
Discover 
